Selman Waksman

Selman Waksman
New York World-Telegram and the Sun staff photographer: Higgins, Roger, photogra · Public domain · source
Name	Selman Waksman
Birth date	22 July 1888
Birth place	Polonne, Volhynian Governorate, Russian Empire
Death date	16 August 1973
Death place	Newark, New Jersey, United States
Nationality	American
Fields	Microbiology, Biochemistry
Institutions	Rutgers University, New Jersey Agricultural Experiment Station
Alma mater	University of Kiev, University of Bern, Rutgers University
Known for	Discovery of streptomycin; antibiotic research; soil microbiology
Awards	Nobel Prize in Physiology or Medicine, National Medal of Science

Selman Waksman was a Ukrainian-born American microbiologist and biochemist known for leading research that produced streptomycin and launched systematic searches for antibiotics from soil organisms. He trained in Eastern Europe and Switzerland before establishing a prolific career at Rutgers, where he supervised researchers and developed methods that influenced pharmaceutical discovery, public health, and biomedical institutions.

Early life and education

Waksman was born in Polonne in the Volhynian Governorate of the Russian Empire and later emigrated to the United States, linking his formative years to figures and places such as Kiev and Bern where he pursued studies at the University of Kiev and the University of Bern. He completed doctoral and postgraduate training that connected him with laboratories in Berlin, Vienna, and Geneva, and later received degrees from Rutgers University where he became associated with the New Jersey Agricultural Experiment Station. His mentors and contemporaries included scientists associated with institutions such as Columbia University, Johns Hopkins University, Harvard University, University of Pennsylvania, and Yale University, while the scientific milieu involved names like Robert Koch, Louis Pasteur, Paul Ehrlich, and Alexander Fleming that framed early 20th-century microbiology.

Career and research

At Rutgers University and the New Jersey Agricultural Experiment Station, Waksman built a research program that connected soil science, microbiology, and pharmaceutical chemistry, collaborating indirectly with entities such as Merck & Co., Pfizer, Eli Lilly and Company, and Bristol-Myers Squibb. He established laboratory techniques that drew on prior work from laboratories at Pasteur Institute, Rockefeller Institute, and Carnegie Institution while training students and postdocs who later joined faculties at Cornell University, University of California, Berkeley, Massachusetts Institute of Technology, University of Chicago, and Stanford University. Waksman's leadership fostered interaction with agencies like the United States Public Health Service, National Institutes of Health, Food and Drug Administration, and philanthropic bodies including the Guggenheim Foundation and the Carnegie Corporation. His program emphasized the screening of actinomycetes and other soil microbes, aligning with contemporary projects at Wistar Institute, Scripps Research, and industrial laboratories such as Squibb and Burroughs Wellcome.

Discovery of streptomycin and antibiotics

Waksman's laboratory isolated antimicrobial compounds from actinomycetes obtained from soil, culminating in the characterization of streptomycin as an effective agent against Mycobacterium tuberculosis, building on earlier antimicrobial milestones like penicillin discovered by Alexander Fleming and subsequent development at Oxford University by Howard Florey and Ernest Boris Chain. The discovery connected with clinical deployments involving hospitals such as Bellevue Hospital, Johns Hopkins Hospital, and Massachusetts General Hospital, and public health responses coordinated with World Health Organization programs and national tuberculosis campaigns like those organized by the American Lung Association and American Thoracic Society. The translation of streptomycin to medical use involved partnerships with pharmaceutical producers including Pfizer and Merck & Co., regulatory review by the Food and Drug Administration, and influence on therapeutic guidelines from institutions like Centers for Disease Control and Prevention and National Tuberculosis Association. The methods Waksman promoted—systematic soil screening, fermentation optimization, and compound purification—were incorporated into discovery pipelines at GlaxoSmithKline, AbbVie, Novartis, Roche, and various academic drug-discovery centers.

Nobel Prize and controversies

In 1952 Waksman was awarded the Nobel Prize in Physiology or Medicine for his work on streptomycin and antibiotics, an honor situated among laureates such as Albert Schweitzer, Alexander Fleming, and Edward Calvin Kendall. The Nobel recognition intersected with disputes over credit and patents: tensions involved his colleagues and students, notably Albert Schatz, and legal contests that implicated institutions like Rutgers University and companies such as Merck & Co. and Eli Lilly. The controversies resonated with broader historical debates about intellectual property, similar to disputes seen in cases involving Rosalind Franklin, Maurice Wilkins, and the structure of DNA controversy or patent battles involving G.D. Searle & Co. and the oral contraceptive developments. Waksman's role in patent assignment and royalties was examined in courts and covered in media outlets including The New York Times, Time (magazine), and Scientific American, while professional responses came from societies like the National Academy of Sciences, American Society for Microbiology, and the Royal Society.

Later career and legacy

After the Nobel Prize, Waksman continued research and advisory activities with organizations such as the National Science Foundation, World Health Organization, United Nations Educational, Scientific and Cultural Organization, and academic institutions including Rutgers University where his laboratory legacy persisted through centers and collections at museums like the Smithsonian Institution and archives at the Library of Congress. His influence extended into public policy discussions involving U.S. Congress committees, shaping funding patterns at the National Institutes of Health and building links with industrial research departments at DuPont and General Electric through consultancy. Waksman's impact is memorialized in awards, buildings, and professorships named at institutions such as Rutgers University and recognition from bodies like the National Medal of Science, the American Philosophical Society, and the Royal Society of Medicine. His methodological contributions underpin contemporary antibiotic discovery at universities and companies including University of Oxford, Imperial College London, ETH Zurich, Max Planck Society, Scripps Research Institute, and biotech firms such as Genentech, Amgen, and Moderna—even as antimicrobial resistance research engages agencies like the Centers for Disease Control and Prevention, World Health Organization, and European Medicines Agency in modern public health responses.

Category:1888 births Category:1973 deaths Category:American microbiologists Category:Nobel laureates in Physiology or Medicine